Hematology · Medical Literature
Efficacy and safety of durcabtagene autoleucel in a phase 1 trial for patients with relapsed/refractory multiple myeloma.
Abstract
Traditional manufacturing of B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapies is prolonged, leading to reduced patient access, T cell exhaustion, and consequently limiting therapeutic efficacy. To address this issue, we developed durcabtagene autoleucel, a BCMA-directed CAR T cell therapy manufactured using a rapid platform aimed at preserving T cell stemness. Here, we present the primary findings of part A of a phase 1 study (NCT04318327) of durcabtagene autoleucel in patients with relapsed/refractory multiple myeloma (r/r MM). The primary objective was safety; secondary objectives included response rates, cellular kinetics, immunogenicity, and manufacturing feasibility. Durcabtagene autoleucel was successfully manufactured for all 55 patients (median vein-to-vein time, 24 days) and given as a single infusion at one of four flat target doses (2.5 × 106 to 20 × 106 CAR T cells). Among all patients, the overall response rate was 98%, and the stringent complete response rate was 55%. Eighty percent of evaluable patients (35 of 44) achieved minimal residual disease negativity. There were no unexpected safety findings and no reports of delayed neurotoxicity. Immunophenotyping and transcriptomic analyses confirmed preservation of a stem-like phenotype in the manufactured final product. On the basis of the safety, efficacy, and cellular expansion results from the phase 1 trial, a phase 2 trial (NCT05172596) was initiated to further explore the efficacy and safety of durcabtagene autoleucel in heavily pretreated patients with aggressive r/r MM.
Clinical relevance
Is durcabtagene autoleucel, a rapidly manufactured BCMA-directed CAR T cell therapy designed to preserve T cell stemness, safe and effective in patients with relapsed/refractory multiple myeloma? __SNAPSHOT__ {"studyDesign":"Phase 1, multicenter, dose-escalation and dose-expansion study (Part A; NCT04318327)","setting":"Multicenter; includes Dana-Farber Cancer Institute and other academic medical centers; country not reported in abstract","sampleSize":"n=55 (all infused; 44 evaluable for MRD)","population":"Adults with relapsed/refractory multiple myeloma (r/r MM); heavily pretreated population; prior data cuts indicate approximately 94% triple-class refractory and 84% with prior hematopoietic stem cell transplant","intervention":"Durcabtagene autoleucel (PHE885): autologous BCMA-directed CAR T cell therapy (fully human anti-BCMA scFv fused to 4-1BB/CD3ζ signaling domains) manufactured via the rapid T-Charge platform (manufacturing time <2 days ex vivo), administered as a single infusion at one of four flat target doses (2.5 × 10⁶ to 20 × 10⁶ CAR T cells)","comparator":"Not applicable (single-arm study)","primaryOutcome":"Safety (adverse events, unexpected toxicities)","followUp":"Not reported in abstract","fundingSource":"Novartis (industry-sponsored; developer of durcabtagene autoleucel)"}
Key findings
Among all 55 treated patients, the overall response rate (ORR) was 98% and the stringent complete response (sCR) rate was 55%. MRD negativity was achieved in 80% of evaluable patients (35 of 44). Manufacturing was feasible in 100% of patients, with a median vein-to-vein time of 24 days. There were no unexpected safety findings and no reports of delayed neurotoxicity. Immunophenotyping and transcriptomic analyses confirmed preservation of a stem-like, non-exhausted T cell phenotype in the manufactured final product. Confidence intervals, p-values, duration of response, progression-free survival, and overall survival data are not reported in the available abstract. NNT/NNH are not calculable from the available data. Specific adverse event rates and grades are not reported in the abstract.
Practice implications
This phase 1 trial establishes that durcabtagene autoleucel can be manufactured rapidly (median 24-day vein-to-vein time, compared to conventional platforms requiring substantially longer) for all enrolled patients, addressing a known access barrier for CAR T cell therapy. The 98% ORR and 55% sCR rate are numerically striking in a heavily pretreated r/r MM population; however, these are single-arm, non-comparative findings from a primary safety study and must be interpreted cautiously—no randomized control arm exists, historical response rates differ by patient population and prior therapy exposure, and duration of response data are not available in the abstract. The MRD negativity rate of 80% is high relative to older approved BCMA-directed CAR T products (e.g., ide-cel MRD-negativity ~26% in KarMMa). Whether these deep responses are durable cannot be determined from the current data. The finding that the product retains a naive-like, non-exhausted phenotype is mechanistically consistent with the manufacturing rationale but requires longer follow-up to confirm clinical durability. Patients who were excluded from or underrepresented in this trial (e.g., those with significant organ dysfunction, prior CAR T exposure, or very short apheresis-to-need intervals) are not well characterized in the available abstract. Because only an abstract is available, these conclusions are based on incomplete data reporting and should be interpreted accordingly. __LIMITATIONS__ 1. Phase 1 design with primary endpoint of safety, not powered or designed to establish comparative efficacy. 2. Single-arm study: no randomized comparator, making attribution of response rates to the therapy alone difficult. 3. Abstract-only availability: key data including duration of response, progression-free survival, overall survival, and detailed adverse event frequency and severity are not reported. 4. Relatively small sample size (n=55) limits detection of rare or delayed toxicities. 5. Follow-up duration not reported; long-term durability of responses and late-onset toxicities (e.g., delayed neurotoxicity, cytopenias) cannot be assessed. 6. Industry sponsorship by Novartis introduces potential for reporting and analysis bias. 7. Generalizability is limited: the enrolled population appears enriched for heavily pretreated patients at academic centers, and applicability to community settings or patients with less aggressive pretreatment histories is unclear. 8. The 44-patient MRD-evaluable subset (vs. 55 treated) introduces a potential denominator discrepancy that may affect interpretation of the MRD negativity rate. 9. Surrogate endpoints (ORR, MRD negativity) have not yet been linked to survival benefit in this trial. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ Durcabtagene autoleucel, manufactured via the rapid T-Charge platform with a 24-day median vein-to-vein time, demonstrated a 98% ORR and 80% MRD negativity rate with no unexpected toxicities in 55 heavily pretreated r/r MM patients in a phase 1 safety study. These early signals are hypothesis-generating and encouraging, but absence of a comparator arm, limited follow-up, and abstract-only data availability preclude conclusions about durability or superiority to existing BCMA-directed therapies. Practice should not change on the basis of this phase 1 report; confirmation from the initiated phase 2 trial (NCT05172596) with mature survival endpoints is required before clinical adoption.